Advanced MRI Protocols to Discriminate Glioma From Treatment Effects: State of the Art and Future Directions. Front Radiol 2022;2:809373
Date
04/15/2022Pubmed ID
37492687Pubmed Central ID
PMC10365126DOI
10.3389/fradi.2022.809373Scopus ID
2-s2.0-85133003459 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
In the follow-up treatment of high-grade gliomas (HGGs), differentiating true tumor progression from treatment-related effects, such as pseudoprogression and radiation necrosis, presents an ongoing clinical challenge. Conventional MRI with and without intravenous contrast serves as the clinical benchmark for the posttreatment surveillance imaging of HGG. However, many advanced imaging techniques have shown promise in helping better delineate the findings in indeterminate scenarios, as posttreatment effects can often mimic true tumor progression on conventional imaging. These challenges are further confounded by the histologic admixture that can commonly occur between tumor growth and treatment-related effects within the posttreatment bed. This review discusses the current practices in the surveillance imaging of HGG and the role of advanced imaging techniques, including perfusion MRI and metabolic MRI.
